AbCellera Biologics (ABCL) Other Operating Expenses (2020 - 2023)

Historic Other Operating Expenses for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to $6.7 million.

  • AbCellera Biologics' Other Operating Expenses fell 5590.18% to $6.7 million in Q4 2023 from the same period last year, while for Sep 2024 it was $6.7 million, marking a year-over-year decrease of 8031.22%. This contributed to the annual value of $91.1 million for FY2024, which is 25341.22% up from last year.
  • As of Q4 2023, AbCellera Biologics' Other Operating Expenses stood at $6.7 million, which was down 5590.18% from $6.1 million recorded in Q3 2023.
  • AbCellera Biologics' Other Operating Expenses' 5-year high stood at $49.6 million during Q1 2022, with a 5-year trough of $667000.0 in Q3 2020.
  • In the last 4 years, AbCellera Biologics' Other Operating Expenses had a median value of $7.6 million in 2021 and averaged $14.1 million.
  • As far as peak fluctuations go, AbCellera Biologics' Other Operating Expenses soared by 246112.76% in 2021, and later crashed by 8712.62% in 2023.
  • Over the past 4 years, AbCellera Biologics' Other Operating Expenses (Quarter) stood at $32.7 million in 2020, then decreased by 15.36% to $27.7 million in 2021, then tumbled by 44.81% to $15.3 million in 2022, then plummeted by 55.9% to $6.7 million in 2023.
  • Its Other Operating Expenses stands at $6.7 million for Q4 2023, versus $6.1 million for Q3 2023 and $6.5 million for Q2 2023.